US-based biopharmaceutical firm FibroGen has secured approval from the China Food and Drug Administration (CFDA) to initiate a Phase II/III clinical trial of roxadustat to treat anaemia associated with lower risk myelodysplastic syndromes (MDS).

Roxadustat (FG-4592) is an oral, small molecule, hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) being developed to enhance endogenous erythropoietin, iron regulation and minimise hepcidin for promoting erythropoiesis.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The two-part Phase II/III trial will assess the safety and efficacy of roxadustat to treat anaemia in non-transfusion dependent, lower risk MDS patients.

The open-label Phase II part of the trial will enrol up to 40 patients, while the randomised, double-blind, placebo-controlled Phase III part will see an enrolment of 135 subjects.

“The two-part Phase II/III trial will assess the safety and efficacy of roxadustat to treat anaemia in non-transfusion dependent, lower risk MDS patients.”

The product is being developed and commercialised by FibroGen and AstraZeneca in select markets such as China and the US, while FibroGen is responsible for clinical trials and regulatory submissions in the countries and will retain all regulatory licences and manufacturing permits in China.

FibroGen also intends to begin a randomised, double-blind, placebo-controlled Phase III clinical trial in the third quarter of this year to investigate the efficacy and safety of roxadustat in transfusion-dependent lower risk MDS patients with anaemia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The product is also being evaluated further for the treatment of anaemia associated with chronic kidney disease (CKD).

It has been studied in Phase I and Phase II trials in more than 1,400 CKD patients.

A total of 15 Phase III trials are being planned with an enrolment of 10,000 non-dialysis-dependent and dialysis-dependent CKD patients in the US, Europe, Japan and China.